Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB

Keyphrases

• ErbB 100%
• Leptin 100%
• Luminal Breast Cancer 100%
• Hyperleptinemia 100%
• MED1 100%
• MiR-205 100%
• Adiponectin 25%
• Obesity 25%
• Coactivator 25%
• Negative Effects 25%
• Human Epidermal Growth Factor Receptor 2 (HER2) 25%
• Obese Mice 25%
• Poor Response 25%
• Honokiol 25%
• Breast Tumor 12%
• Phosphorylation 12%
• Molecular Mechanism 12%
• Responsive Genes 12%
• Tumor Growth 12%
• Growth Inhibition 12%
• Hormonal Therapy 12%
• Gene Repression 12%
• Response to Therapy 12%
• Tumor Progression 12%
• Mechanistic Insight 12%
• Functional Activation 12%
• Nuclear Translocation 12%
• Non-obese 12%
• Obese Women 12%
• In Silico Analysis 12%
• Bioactive Compounds 12%
• Mediated Growth 12%
• Corepressor 12%
• Adipocytokines 12%
• NCoR 12%
• Hormone Receptor-positive Breast Cancer 12%
• Signature Genes 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Tamoxifen 100%
• Hyperleptinemia 100%
• Leptin 80%
• Adiponectin 20%
• Epidermal Growth Factor Receptor 20%
• Tumor Growth 20%
• Mouse Mutant 20%
• Honokiol 20%
• Hormone Receptor 10%
• Breast Tumor 10%
• Hormone Cancer Therapy 10%
• Adipocytokine 10%
• microRNA 205 10%

Biochemistry, Genetics and Molecular Biology

• ErbB 100%
• Leptin 100%
• Adiponectin 25%
• Epidermal Growth Factor Receptor 25%
• Tumor Progression 25%
• Mouse Mutant 25%
• Honokiol 25%
• Hormone Receptor 12%
• Growth Inhibition 12%
• Gene Repression 12%
• Computer Model 12%
• Corepressor 12%
• Adipokine 12%
• Gene Signature 12%